Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — Investor Presentation (September 2020)
19 slides from Dr. Reddy's Laboratories's investor presentation, September 2020
Slide 1: Driven by the Belief that
Dr.Reddy’s es Driven by the Belief that
Slide 2: One Purpose
One Purpose 23000+ people We accelerate access to affordable and innovative medicines 45+ nationalities because 400+ products 40+ countries 2
Slide 3: Our Purpose guides our commitment
Our five promises clarify what we do, Our Purpose Bringing Addressing what we offer guides our expensive medicine unmet and the within reach patient needs commitments commitment we make to our to our 1 2 stakeholders. Enabling and As we keep the customers helping our partners ensure 5 3 Helping inte
Slide 4: Three core business segments
As an integrated global pharmaceutical enterprise, we operate through three core business segments: Pharmaceutical Global Generics Proprietary Services & Active Products Ingredients Partner of Choice Access to affordable medicines Fulfilling unmet medical needs Global leader in integrated Finished d
Slide 5: Significant success in highly regulated markets
We have had significant success in highly regulated markets… Revenue split by business Split of GG business by Geography 6% 14% North America 37% Emerging Markets 19% India 17% 80% Europe 7% Proprietary Products & Others PSAI Global Generics Revenues for FY20 - $2.3 Bn
Slide 6: Presence in all major regions of the world
...with presence in all major regions of the world 9 API Manufacturing Facilities Commercial Presence in 13 42 Formulations Manufacturing Facilities Countries 9 ALGERIA COLOMBIA KAZAKHSTAN ROMANIA UK Global AUSTRALIA FRANCE MALAYSIA RUSSIA UKRAINE R&D Centres BANGLADESH GERMA
Slide 7: Science and technology for affordable, innovative medicines
We use science and technology In FY2020 to provide affordable and innovative medicines. Our R&D Strengths 8 10 168 ANDAs DMFs New products launched State-of-the-art R&D centers in India, U.K., U.S. & Netherlands in US including 4 re-launches Over 1400+ research scientists working on various projects
Slide 8: First to launch tough-to-make products
We strive to be the first to launch tough-to-make products and differentiated formulations IP and technology-driven active ingredients Complex generics and biologics Differentiated formulations and novel products for unmet needs Dr. Reddy’s at a glance 10/8/2020 8
Slide 9: Recognized for strong corporate governance
We are recognized for our strong India’s Best corporate governance Managed Board Our Board was named one of India’s best managed boards by Mint and Aon Hewitt and by Economic Times and Hays in their respective studies We were declared Indian MNC of the year at the All India Management Associatio
Slide 10: Our people practices across the markets we operate in
Great Place Our people practices to Work® across the markets we operate in We were ranked India’s Best Companies To Work For among biotechnology and pharmaceutical companies by Great Place to Work®, in 2017 Best Places to Work in 2017 in New Jersey by NJBIZ We were featured in the first Sector
Slide 11: A strong commitment to the community
A strong commitment to the community School Improvement Program (SIP): SIP aims at ensuring continuous quality education to students from less privileged backgrounds. Through this program, Dr. Reddy’s has played an important role in shaping the lives of over 1,00,000 students from 229 Government sch
Slide 12: Driving the 9 pillars of sustainable operations
Driving the 9 pillars of Started our sustainability sustainable operations efforts in 2004, which was a pioneering effort back then We have been able to fully integrate sustainability in our core operations through well documented progress on our 9 pillars: People We became the first Indian Safety p
Slide 13: Our Journey
Our Journey “Charting out a course in unknown waters and learning along the way has made the difference to us.” - Satish Reddy, Chairman Dr. Reddy’s at a glance 10/8/2020 13
Slide 14: Our journey has covered six phases (1984-1991)
Our journey has covered six phases 1984 1991 The birth of From a dream molecules to affordable medicines Scientist and entrepreneur, Dr. K. Anji Reddy establishes Having successfully made active ingredients accessible, Dr. Dr. Reddy’s Laboratories with a vision of making medicines Reddy’s focuses on
Slide 15: Our journey has covered six phases (1995-2007)
Our journey has covered six phases 1995 2007 Expanding to Accelerating reach patients access to in other expensive countries therapies Realizing the importance of making innovative medicines Staying sharply focused on patient needs, Dr. Reddy’s focuses more accessible the world over, Dr. Reddy’s cre
Slide 16: Our journey has covered six phases (2010-2015)
Our journey has covered six phases 2010 2015 From Re-dedicating medicines ourselves to to health patient- centricity Taking a holistic view of patient needs, Dr. Reddy’s focuses Having built a diverse set of global businesses, on creating and rolling out a number of programs to help Dr. Reddy’s unit
Slide 17: Our Future
Our Future “We are impacting millions of patients by empowering our people to act with agility and to do what is tough and worthwhile.” - G V Prasad, CEO Dr. Reddy’s at a glance 10/8/2020 17
Slide 18: Dr. K. Anji Reddy
“The mission is to improve the quality of life and life expectancy itself. This requires good science. But for science to be good, it has to result in affordable medicine.” Dr. K. Anji Reddy Founder, Dr. Reddy’s
Slide 19: Contact
CONTACT About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr
Dr. Reddy's Laboratories — Investor Presentation (September 2020) on 6ix